Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study

[1]  C. Kuhn,et al.  Menstrual cycle effects on caffeine elimination in the human female , 2005, European Journal of Clinical Pharmacology.

[2]  I. G. Fantus,et al.  Insulin and related factors in premenopausal breast cancer risk , 2004, Breast Cancer Research and Treatment.

[3]  A. Smith.  Intrinsic Hepatic Phenotype Associated with the Cyp1a2 Gene as Shown by cDNA Expression Microarray Analysis of the Knockout Mouse , 2003, EHP toxicogenomics : journal of the National Institute of Environmental Health Sciences.

[4]  N F Boyd,et al.  The association of breast mitogens with mammographic densities , 2002, British Journal of Cancer.

[5]  K. Kyvik,et al.  The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. , 2002, Pharmacogenetics.

[6]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[7]  K. Bruckdorfer,et al.  Stimulation of progesterone production in human granulosa-lutein cells by lipoproteins: evidence for cholesterol-independent actions of high-density lipoproteins. , 2002, The Journal of endocrinology.

[8]  G. Jürgens,et al.  Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men , 2002, Clinical pharmacology and therapeutics.

[9]  B. Hoffman,et al.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Berglund,et al.  Breast cancer incidence in ex‐smokers in relation to body mass index, weight gain and blood lipid levels , 2001, European Journal of Cancer Prevention.

[11]  D. Grabrick,et al.  Evidence for a major gene influence on abdominal fat distribution: The Minnesota breast cancer family study , 2001, Genetic epidemiology.

[12]  D. Stocco.  StAR protein and the regulation of steroid hormone biosynthesis. , 2001, Annual review of physiology.

[13]  F. Berrino,et al.  Estrogen Metabolism and Risk of Breast Cancer: a Prospective Study of the 2:16␣-hydroxyestrone Ratio in Premenopausal and Postmenopausal Women , 2022 .

[14]  M. Thun,et al.  Passive smoking exposure and female breast cancer mortality. , 2000, Journal of the National Cancer Institute.

[15]  S. Haffner.  Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation , 2000, International Journal of Obesity.

[16]  A. Nafziger,et al.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.

[17]  A. Duncan,et al.  Menstrual cycle effects on urinary estrogen metabolites. , 1999, The Journal of clinical endocrinology and metabolism.

[18]  M. Folan,et al.  Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women , 1999, Journal of clinical pharmacology.

[19]  U. Fuhr,et al.  Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. , 1999, Pharmacogenetics.

[20]  S. Cnattingius,et al.  Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. , 1999, British journal of clinical pharmacology.

[21]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[22]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[23]  K. Overvad,et al.  A woman's build and the risk of breast cancer. , 1998, European journal of cancer.

[24]  O. Olopade,et al.  Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. , 1998, Journal of the National Cancer Institute.

[25]  H. Yamazaki,et al.  Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. , 1998, Chemical research in toxicology.

[26]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[27]  G. Kearns,et al.  Quantitation of three‐month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N‐acetyltransferase‐2, and xanthine oxidase activity determined with caffeine phenotyping , 1998, Clinical pharmacology and therapeutics.

[28]  D. Schrenk,et al.  A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers , 1998, European Journal of Clinical Pharmacology.

[29]  U. de Faire,et al.  Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. , 1997, The Journal of endocrinology.

[30]  J. Buster,et al.  Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells , 1997, Steroids.

[31]  L. Le Marchand,et al.  Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. , 1997, Pharmacogenetics.

[32]  N. Boyd,et al.  Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk. , 1997, Nutrition and cancer.

[33]  E. Perucca,et al.  The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. , 1996, Therapeutic drug monitoring.

[34]  P. Thomas,et al.  Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[35]  Yager Jd,et al.  Molecular Mechanisms of Estrogen Carcinogenesis , 1996 .

[36]  J. Yager,et al.  Molecular mechanisms of estrogen carcinogenesis. , 1996, Annual review of pharmacology and toxicology.

[37]  C. Ioannides,et al.  Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat. , 1995, European journal of pharmacology.

[38]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[39]  T. Kamataki,et al.  Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[40]  B. Tang,et al.  Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. , 1994, Pharmacogenetics.

[41]  M. Whitehead,et al.  Effect of Continuous Combined Estrogen and Desogestrel Hormone Replacement Therapy on Serum Lipids and Lipoproteins , 1994, Obstetrics and gynecology.

[42]  B. Tang,et al.  The use of caffeine for enzyme assays: A critical appraisal , 1993, Clinical pharmacology and therapeutics.

[43]  G Block,et al.  Comparison of two dietary questionnaires validated against multiple dietary records collected during a 1-year period. , 1992, Journal of the American Dietetic Association.

[44]  C. Ioannides,et al.  Hyperinsulinaemia causes a preferential increase in hepatic P4501A2 activity. , 1992, Biochemical pharmacology.

[45]  B. Tang,et al.  Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities , 1991, Clinical pharmacology and therapeutics.

[46]  B. Tang,et al.  Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping , 1991, Clinical pharmacology and therapeutics.

[47]  C. la Vecchia,et al.  The antiestrogenic effect of cigarette smoking in women. , 1990, American journal of obstetrics and gynecology.

[48]  H. Bradlow,et al.  Dietary and Pharmacological Control of Estradiol Metabolism in Humans a , 1990, Annals of the New York Academy of Sciences.

[49]  H. Higa.  [Effects of catecholestrogen and catecholestrogen 2-monomethyl ether on serum lipids and lipoproteins in rats]. , 1990, Igaku kenkyu. Acta medica.

[50]  D. Anderson,et al.  Serum steroid binding proteins and the bioavailability of estradiol in relation to breast diseases. , 1985, Journal of the National Cancer Institute.

[51]  H. Bush,et al.  Breast Cancer Research , 1978, British Journal of Cancer.

[52]  David C. Anderson,et al.  SEX‐HORMONE‐BINDING GLOBULIN , 1974, Clinical endocrinology.